natgillin/translations-raw huggingface dataset:
Water or other liquid is not needed to swallow the dose.
Da pogoltnete odmerek, ne boste potrebovali vode ali druge tekočine.
water retention
zadrževanje vode
water retention
zastajanje tekočine
water retention
zastajanje vode
water retention (oedema)
zastajanje vode (edemi)
Water retention (which shows as puffy fingers or swollen ankles, for a short time at the start of treatment)
Pri otrocih zastajanje vode (kar se kaže kot nabrekli prsti ali otekli gležnji za kratek čas po začetku zdravljenja)
Water retention leading to swelling of the hands, ankles or feet.
zadrževanje vode, ki vodi v otekanje rok, gležnjev ali nog
Water should flow slowly onto powder.
Voda mora na prašek teči počasi.
water tablets (diuretics of thiazide type)
zdravila za odvajanje vode (tiazidni diuretiki)
water tablets (‘diuretics’) which are used to increase the amount of water you produce
tablete za odvajanje vode ("diuretike"), ki se uporabljajo za povečanje izločanja vode iz telesa
Water with a high concentration of calcium should not be used.
Vode z veliko koncentracijo kalcija ne smete piti.
Water with a high concentration of calcium should not be used.
Vode z visoko vsebnostjo kalcija ne smete uporabiti.
Water, purified Propylene glycol Hydroxypropylcellulose Sodium laurilsulfate Brilliant blue (E133) Tartrazine (E102)
Prečiščena voda Propilenglikol Hidroksipropilceluloza Natrijev lavrilsulfat Briljantno modro FCF (E133) Tartrazin (E102)
Waterproof gloves must be utilised in the preparation and during the determination of radiochemical purity of [90Y]-radiolabelled Zevalin.
Med pripravo preparata in določanjem radiokemijske čistote z [90Y] označenega zdravila Zevalin je treba uporabljati vodotesne rokavice.
Watery eyes
olzenje oči;
watery eyes
olzne oči
Watery eyes
Solzne oči
Watery fluid coming out of your wound or nose (CSF leakage/CSF rhinorrhea)
vodi podobna tekočina, ki izteka iz rane ali nosu (uhajanje likvorja/likvorska rinoreja),
way in.
popolnoma
WBC
Levkociti
WBC < 10 x 109/l, platelet < 450 x 109/l, myelocyte+metamyelocyte < 5% in blood, no blasts and promyelocytes in blood, basophils < 20%, no extramedullary involvement
WBC < 10 x 109/l, trombociti < 450 x 109/l, mielociti+metamielociti < 5 % v krvi, brez blastov in promielocitov v krvi, bazofilci < 20 %, brez ekstramedularne prizadetosti
WBC cystine level (LS Mean ± SE) in nmol hemicystine/mg protein
Vrednost cistina v belih krvnih celicah (povprečje najmanjših kvadratov ± SN) v nmol hemicistina/mg beljakovin
WC
DN
WCBP must be able to comply with effective contraceptive measures.
Ženske v rodni dobi morajo biti sposobne zadostiti vsem zahtevam glede učinkovite kontracepcije.
We suggest you write the date of your most recent test and also of your next test (ask your doctor for the date) on the Patient Alert Card, to help you remember when your next test is due.
Predlagamo, da si datum zadnje in naslednje preiskave (zdravnika prosite za datum) zapišete na Opozorilno kartico za bolnika, da si boste lažje zapomnili, kdaj imate naslednjo preiskavo.
weak heart (decompensated cardiac failure) that is not under close medical observation
šibko srce (dekompenzirano srčno popuščanje), ki ni pod skrbnim zdravniškim nadzorom
Weak, numb, tingling or prickling sensations mainly affecting the feet and legs
šibkost, odrevenelost, mravljinčenje, zbadanje, zlasti v stopalih in nogah
Weakening of the blood-glucose-lowering effect and, thus raised blood glucose levels may occur when one of the following active substances is taken, for example:
Ob jemanju katere izmed naslednjih učinkovin se lahko zmanjša učinek na znižanje koncentracije glukoze v krvi, zato lahko v nekaterih primerih pride do hiperglikemije:
weakening of the bones, leading to fractures
oslabitev kosti, ki je vzrok zlomov,
Weaker interactions have been observed with clotrimazole, clarithromycin, josamycin, nifedipine, nicardipine, diltiazem, verapamil, amiodarone, danazol, ethinylestradiol, omeprazole and nefazodone.
Šibkejše interakcije so opazili pri sočasni uporabi s klotrimazolom, klaritromicinom, josamicinom, nifedipinom, nikardipinom, diltiazemom, verapamilom, amiodaronom, danazolom, etinilestradiolom, omeprazolom in nefazodonom.
Weakness
labotnost,
weakness
občutek oslabelosti
weakness
oslabelost
weakness
oslabelost,
weakness
telesna temperatura
Weakness
Šibkost
Weakness
šibkost,
weakness (asthenia)
šibkost (astenija)
weakness (asthenia)
šibkost (astenija),
Weakness (asthenia).
oslabelost (astenija)
Weakness (asthenia).
šibkost (astenija) visok krvni tlak.
weakness (asthenia);
šibkost (astenija),
weakness (fatigue) headache
utrujenost glavobol
Weakness (Lethargy)
Zaspanost, otopelost (letargija)
Weakness and fatigue, which could be side effects caused by other medicines.
Oslabelost in utrujenost, ki sta lahko neželena učinka, povzročena z drugimi zdravili.
weakness and pain in the feet and hands (Guillain-Barré syndrome)
šibkost in bolečine v stopalih in dlaneh (Guillain-Barréjev sindrom)
Weakness and tiredness, fever
šibkost in utrujenost, zvišana telesna temperatura
weakness beginning in the hands and feet and moving up towards the trunk of the body palpitations, tremor or hyperactivity
oslabelost, ki se najprej pojavi v dlaneh in stopalih in se nato širi proti trupu palpitacije, tremor ali hiperaktivnost
weakness beginning in the hands and feet and moving up towards the trunk of the body palpitations, tremor or hyperactivity
oslabelost, ki se začne v dlaneh in stopalih in se premika proti trupu razbijanje srca (palpitacije), tresavica ali hiperaktivnost
weakness beginning in the hands and feet and moving up towards the trunk of the body palpitations, tremor or hyperactivity.
oslabelost, ki se začne v dlaneh in stopalih in se premika proti trupu razbijanje srca (palpitacije), tresavica ali hiperaktivnost
weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity.
oslabelost, ki se najprej pojavi v dlaneh in stopalih in se nato širi proti trupu, palpitacije, tremor ali hiperaktivnost.
weakness generalised swelling
šibkost generalizirano otekanje
weakness headache
oslabelost glavobol
Weakness in children
oslabelost pri otrocih
weakness or paralysis of the limbs or face, difficulty speaking, severe headache, seeing, feeling or hearing things that are not there (signs of nervous system disorders)
šibkost ali ohromelost okončin ali obraza, težave pri govoru, hud glavobol, vidne, čutne ali slušne zaznave nečesa, kar v resnici ne obstaja (znaki okvar živčevja)
Weakness or reduced sensation or tingling in the limbs
šibkost ali zmanjšanje občutenja ali ščemenje v udih
weakness), anorexia rare: hyperglycaemia* very rare: diabetes mellitis*
anoreksija redki: hiperglikemija* zelo redki: sladkorna bolezen
weakness), anorexia rare: hyperglycaemia* very rare: diabetes mellitis*
redki: hiperglikemija* zelo redki: sladkorna bolezen
weakness,
oslabelost,
weakness, bruising and frequent infections (aplastic anaemia)
šibkost, podplutbe in pogoste okužbe (aplastična anemija)
weakness, bruising, fever and frequent infections stiffness
oslabelost, podplutbe, zvišana telesna temperatura in pogoste okužbe okorelost
weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction swelling of the face, lips, tongue and throat (Quincke’s oedema) flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS])
šibkost, vrtoglavico ali omotico ali težave z dihanjem, saj so to lahko znaki resne alergijske (anafilaktične) reakcije otekanje obraza, ustnic, jezika in žrela (Quinckejev edem) gripi podobne simptome in izpuščaj na obrazu, ki se v nadaljevanju razširi in ga spremlja visoka temperatura, zvišane vrednosti jetrnih encimov pri krvnih testih in povečanje števila določenega tipa belih krvnih celic (eozinofilija) ter povečane bezgavke (reakcija na zdravilo z eozinofilijo in sistemskimi simptomi [DRESS]
weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction swelling of the face, lips, tongue and throat (Quincke’s oedema) flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]),.
šibkost, vrtoglavico ali omotico ali težave z dihanjem, saj so to lahko znaki resne alergijske (anafilaktične) reakcije otekanje obraza, ustnic, jezika in žrela (Quinckejev edem) gripi podobne simptome in izpuščaj na obrazu, ki se v nadaljevanju razširi in ga spremlja visoka temperatura, zvišane vrednosti jetrnih encimov pri krvnih testih in povečanje števila določenega tipa belih krvnih celic (eozinofilija) ter povečane bezgavke (reakcija na zdravilo z eozinofilijo in sistemskimi simptomi [DRESS]
weakness, feeling unwell
šibkost, slabo počutje
weakness, fever, chills (rigor)
labost, zvišana telesna temperatura, mrzlice (tresavica)
Weakness, fever, pain
šibkost, zvišana telesna temperatura, bolečine
weakness, generally feeling unwell,
oslabelost, splošno slabo počutje,
weakness, injection site reactions including pain
šibkost, reakcije na mestu injiciranja, vključno z bolečino
weakness, lack of strength and energy, excessive tiredness and unusual sleepiness (asthenia/fatigue)
oslabelost, pomanjkanje moči in energije, pretirana utrujenost in neobičajna zaspanost (astenija/izčrpanost)
weakness, loss of strength or extreme tiredness high blood levels of the enzyme creatine phosphokinase
šibkost, izguba moči ali huda utrujenost, visoka raven encima kreatin fosfokinaze v krvi.
Weakness, pyrexia, anasarca, chills, rigors
oslabelost, zvišana telesna temperatura, anasarka, mrazenje, okorelost
Weakness, spontaneous bleeding or bruising and frequent infections with signs such as fever, chills, sore throat or mouth ulcers (signs of low level of blood cells, also known as pancytopenia)
šibkost, spontane krvavitve in pojavljanje modric ter pogoste okužbe z znaki, kot so zvišana telesna temperatura, mrazenje, vnetje grla oziroma žrela, razjede ustne sluznice (znaki zmanjšanega števila krvnih celic, kar imenujemo tudi pancitopenija)
weakness, swollen face, shivering, change in your sense of taste, tooth disorder
šibkost, otečen obraz, drgetanje, spremembe okusa, težave z zobmi
Weakness, thirst, chest tightness
šibkost, žeja, tiščanje v prsih
Weakness, thirst, chest tightness.
Šibkost, žeja, tiščanje v prsih.
Weakness, thirst, chest tightness.
šibkost, žeja, tiščanje v prsih
Weakness, tiredness
šibkost, utrujenost
weakness, tiredness, fever or flu like symptoms
šibkost, utrujenost, vročina ali gripi podobni simptomi
Weakness, tiredness, headache
šibkost, utrujenost, glavobol
Weakness/gap in abdominal muscles and out pouching of skin over healed incision, hernia on the stomach wall
oslabelost/vrzel med mišicami trebušne stene in pojav izbokline kože nad zaceljeno kirurško rano, kila trebušne stene,
Weaner
Odstavljenec
Weaning should be attempted at least every 12 hours when the patient is stable on a low dose of INOmax.
Prekinitev je treba opraviti vsaj 12 ur po stabilizaciji bolnika z majhnim odmerkom zdravila INOmax.
wear clothing which protects your skin, including your head and face, arms and legs; use a lip balm and a broad spectrum sunscreen (minimum of Sun Protection Factor (SPF) 30, re-applied every 2 to 3 hours).
nosite oblačila, ki vam varujejo kožo, tudi glavo in obraz, roke in noge, uporabite mazilo za ustnice in sredstvo za sončenje z visoko zaščito (vsaj zaščitni faktor SPF 30; sredstvo znova nanesite vsake 2 do 3 ure).
Wear dark, closely woven clothing.
Nosite temna, gosto tkana oblačila.
Wear impermeable disposable gloves when handling the veterinary medicinal product and handling the oral syringe.
Pri ravnanju z veterinarskim zdravilom in oralno brizgo nosite neprepustne rokavice za enkratno uporabo.
Wear impermeable disposable gloves when handling the veterinary medicinal product.
Med ravnanjem z zdravilom za uporabo v veterinarski medicini nosite neprepustne rokavice za enkratno uporabo.
Wear protective gloves while disposing of vomit, urine or faeces of treated dogs.
Nosite zaščitne rokavice pri odstranjevanju izbruhane vsebine, urina ali blata zdravljenih psov.
Wear protective gown or laboratory coat, safety glasses, or face shield and gloves while preparing or administering Imlygic.
Med pripravo in dajanjem zdravila Imlygic nosite zaščitno obleko ali laboratorijsko haljo, zaščitna očala ali ščitnik za obraz in rokavice.
Wear suitable gloves when handling or applying the product to dogs and cats.
Nosite ustrezne rokavice, ko delate z zdravilom ali ga nanašate na pse in mačke.
Wearing contact lenses - SIMBRINZA contains benzalkonium chloride
Nošenje kontaktnih leč – zdravilo SIMBRINZA vsebuje benzalkonijev klorid
Wearing disposable gloves, apply the cream gently to the lesion.
Nadenite si rokavice za enkratno uporabo in kremo narahlo nanesite na prizadeto mesto.
Wearing gloves, grasp the plaque or indurated portion of the flaccid penis about 1 cm proximal and distal to the injection site.
Oblecite rokavice in plak ali trdi del mlahavega penisa primite približno 1 cm proksimalno in distalno na mesto injiciranja.
wearing protective clothing which also covers your head, neck, arms and legs using a sunscreen with a high protection factor.
uporabljate zaščitna oblačila, ki pokrijejo tudi vašo glavo, vrat, roke in noge, uporabljate sončne kreme z visokim zaščitnim faktorjem.
wearing protective clothing which covers your head, neck, arms and legs using a sunscreen with a high protection factor.
uporabljate zaščitna oblačila, ki pokrijejo tudi vašo glavo, vrat, roke in noge, uporabljate sončne kreme z visokim zaščitnim faktorjem.
weatin g
Potenje
weating
Mono- terapija
weating
potenje
weating
znojenje,
weating (including night sweats)
potenje (vključno nočna potenja)
weating,
potenje,
weating, itching numbness or tingling that occurs in the mucosa or tissues of the oral cavity
znojenje, srbenje otrplost ali mravljinčenje, ki se pojavita v ustni sluznici ali ustnem tkivu
weating, nausea, vomiting or dizziness;
znojenje, navzea, bruhanje ali omotica,
weating, nausea, vomiting or dizziness;
znojenje, navzea, bruhanje ali omotica;
weating, nausea, vomiting or dizziness;
znojenje, siljenje na bruhanje (navzea), bruhanje ali omotica;
weating, night sweats
potenje, nočno potenje
weating, night sweats
potenje, nočno potenje,
weating, night sweats, +skin
urtikarija, znojenje, nočno znojenje,
Wed.
Sre.
Wednesday + Saturday
reda in sobota
Wednesday-Friday).
petek).
Wee k
teden
Week
Redki
Week 0 (after 36 weeks on Treatment)
0. teden (po 36 tednih zdravljenja)
Week 0 Week 2 Week 6 Week 10 Week 14 Week 18 Week 22 Week 26 Study Week
Teden 0 Teden 2 Teden 6 Teden 10 Teden 14 Teden 18 Teden 22 Teden 26 Te de n v študiji
Week 0 Week 2 Week 6 Week 10 Week 14 Week 18 Week 22 Week 26 Study Week
Teden 0 Teden 2 Teden 6 Teden 10 Teden 14 Teden 18 Teden 22 Teden 26 Tede n v študiji
Week 1
teden
Week 1 (day 1-7)
teden (1.-7. dan)
Week 1 (day 1-7):
1. teden (1.–7. dan):
Week 1 (wallets of 14 and 28) Week 2 (wallets of 14 and 28) Week 3 (wallets of 28)
teden (pretisne zgibanke po 14 in 28) teden (pretisne zgibanke po 14 in 28) 3. teden (pretisne zgibanke po 28)
Week 1 + 2
1. + 2. teden
Week 1, 2, 3, 4
Teden 1, 2, 3, 4
Week 1, Week 2
1. teden, 2. teden
WEEK 1, WEEK 2, WEEK 3
1. teden, 2. teden, 3. teden
Week 1.
1. teden
Week 104
104. teden
Week 104
po 104 tednih
Week 104 (n=382)
104. tednu (n=382)
week 104, X-ray data were available for 114 patients, and 77% showed no progression from baseline.
V 104. tednu pa so bili rentgenski podatki na voljo za 114 bolnikov in 77 % jih ni kazalo nikakršnega napredovanja bolezni v primerjavi z začetnimi vrednostmi.
Week 12
po 12 tednih
Week 12 post-transplant (pTVR)b
12. teden po presaditvi (pTVR)b
Week 12 Primary
12. teden primarni cilj opazovanja
Week 12 results showed statistically significant improvement of the signs and symptoms of active non-radiographic axial spondyloarthritis in patients treated with Humira compared to placebo (Table 11).
Rezultati po 12.tednu so pokazali statistično pomembno izboljšanje znakov in simptomov aktivnega ne-radiografskega aksialnega spondiloartritisa pri bolnikih, ki so bili zdravljeni z zdravilom Humira v primerjavi s placebom (preglednica 11).
Week 12 results showed statistically significant improvement of the signs and symptoms of active non-radiographic axial spondyloarthritis in patients treated with Humira compared to placebo (Table 9).
Rezultati po 12.tednu so pokazali statistično pomembno izboljšanje znakov in simptomov aktivnega ne-radiografskega aksialnega spondiloartritisa pri bolnikih, ki so bili zdravljeni z zdravilom Humira v primerjavi s placebom (preglednica 9).
Week 12 to Week 18, inclusive
teden 12 do vključno 18
Week 13 All (N=10)
13. teden Vsi
Week 13 All (N=11)
13. teden Vsi
Week 13 All (N=21)
13. teden Vsi
Week 144 window is between Day 967 and 1,050 (inclusive).
Okno v 144. tednu je med 967 in 1.050 dnevom (vključno z njima).
Week 144b
144. tedenb
Week 156
po 156 tednih
Week 16
po 16 tednih
Week 19 to Week 24, inclusive
teden 19 do vključno 24
Week 1: initial dose of 9 mg (two 4.5 mg tablets) per day.
1. teden: začetni odmerek 9 mg (dve 4,5-miligramski tableti) na dan;
Week 1: One tablet in the morning
1. teden: ena tableta zjutraj;
Week 1: One tablet once a day in the morning
1. teden: ena tableta enkrat dnevno, in sicer zjutraj;
Week 1: Take one tablet daily of Nemdatine 5 mg.
Teden 1: Vzemite 1 tableto zdravila Nemdatin 5 mg dnevno.
Week 2
teden
Week 2 (day 8-14)
teden (8.-14. dan)
Week 2 (day 8-14):
2. teden (8.–14. dan):
Week 2 onwards:
Teden 2 in naprej:
Week 2, Day 8 9 10 11 12 13 14
Teden 2, Dan 8 9 10 11 12 13 14
Week 2-4
2.-4. teden
Week 208
po 208 tednih
Week 22*
22. teden
Week 24
po 24 tednih
Week 24 ACR20, n (%)
24. teden ACR20, n (%)
Week 24 compared with placebo and each monotherapy component (see Table 1).
To se je pokazalo z znižanjem celotnega seštevka SGRQ po 24 tednih v primerjavi s placebom in vsako od sestavin v monoterapiji (glejte preglednico 1).
Week 24 n (%)
24. teden n (%)
Week 24 to end of study
od 24. tedna do konca študije
week 24, all placebo-treated patients crossed over to infliximab induction.
V 24. tednu so vsi s placebom zdravljeni bolniki prešli na uvajanje infliksimaba.
Week 24, all remaining placebo-treated patients were switched to either apremilast 20 or 30 mg BID.
Po 24 tednih so vsem preostalim bolnikom, ki so prejemali placebo, začeli dajati apremilast 20 mg ali 30 mg dvakrat na dan.
Week 24.
24 tednih.
Week 24: ACR/EULAR Boolean Remission, n (%)
24. teden: ACR/EULAR remisija (Boolean), n (%)
Week 25 onwards until disease progression
od 25. tedna dalje, do napredovanja bolezni
Week 26
26.teden
Week 26
4. teden
Week 26
46,7
Week 26
84,8
Week 26
po 26 tednih
Week 26 All (N=10)
26. teden Vsi
Week 26 All (N=11)
26. teden Vsi
Week 26 All (N=21)
26. teden Vsi
Week 260 normal
260. teden4 negativna
Week 2604 negative positive > baseline
izhodiščna vrednost
Week 28
28. teden
Week 2: 7 film-coated tablets of Nemdatine 10 mg
Teden 2: 7 filmsko obloženih tablet Nemdatine 10 mg
Week 2: One tablet in the morning and one tablet in the evening
2. teden: ena tableta zjutraj in ena tableta zvečer;
Week 2: One tablet twice a day, one in the morning and one in the evening
2. teden: ena tableta dvakrat dnevno, ena zjutraj in ena zvečer;
Week 2: Take one tablet daily of Nemdatine 10 mg.
Teden 2: Vzemite 1 tableto zdravila Nemdatin 10 mg dnevno.
Week 2: the dose may be increased to 18 mg (one 18 mg tablet) per day or decreased to 4.5 mg (one 4.5 mg tablet) per day.
2. teden: odmerek se lahko poveča na 18 mg (ena 18-miligramska tableta) na dan ali zmanjša na 4,5 mg (ena 4,5-miligramska tableta) na dan;
Week 3
teden
Week 3 (day 15-21)
3. teden (15.-21. dan)
Week 3 (day 15-21):
3. teden (15.-21. dan)
Week 3 (day 15-21):
3. teden (15.–21. dan):
Week 3 + 4
3. + 4. teden
Week 3, Day 15 16 17 18 19 20 21
Teden 3, Dan 15 16 17 18 19 20 21
Week 32
32. teden
Week 36
12 (32,4 %)
Week 36
36. teden
Week 3: 7 film-coated tablets of Nemdatine 15 mg
Teden 3: 7 filmsko obloženih tablet Nemdatine 15 mg
Week 3: Take one tablet daily of Nemdatine 15 mg.
Teden 3: Vzemite 1 tableto zdravila Nemdatin 15 mg dnevno.
Week 3: the dose may be increased to 36 mg (two 18 mg tablets) per day.
3. teden: odmerek se lahko poveča na 36 mg (dve 18-miligramski tableti) na dan.
Week 3: Three tablets every day, two in the morning and one in the evening
3. teden: tri tablete vsak dan, dve zjutraj in ena zvečer;
Week 3: Two tablets in the morning and one tablet in the evening
3. teden: dve tableti zjutraj in ena tableta zvečer;
Week 4
4.teden
Week 4
po 4 tednih
Week 4 (day 22-28)
4. teden (22.-28. dan)
Week 4 (day 22-28):
Od 4. tedna dalje:
Week 4 (wallets of 28)
4. teden (pretisne zgibanke po 28)
Week 4 and beyond
4. teden in naprej
Week 4 and onward: Two tablets twice a day, two in the morning and two in the evening
4. teden in naprej: dve tableti dvakrat dnevno, dve zjutraj in dve zvečer.
Week 4 and onwards: Two tablets in the morning and two tablets in the evening
4. teden in naprej: dve tableti zjutraj in dve tableti zvečer.
Week 4, Day 22 23 24 25 26 27 28
Teden 4, Dan 22 23 24 25 26 27 28
Week 48
48 tednov
Week 48
po 48 tednih
Week 48 and Week 240 outcomes for patients on the recommended dose of ISENTRESS 400 mg twice daily from STARTMRK are shown in Table 3.
Rezultati po 48. in 240. tednih preskušanja STARTMRK so za bolnike, ki so prejemali priporočeni odmerek 400 mg zdravila ISENTRESS dvakrat na dan, prikazani v preglednici 3.
Week 48 and Week 240 outcomes for patients on the recommended dose of ISENTRESS 400 mg twice daily from STARTMRK are shown in Table 4.
Rezultati po 48. in 240. tednih preskušanja STARTMRK so za bolnike, ki so prejemali priporočeni odmerek 400 mg zdravila ISENTRESS dvakrat na dan, prikazani v preglednici 4.
Week 48 and Week 240 outcomes for patients on the recommended dose of ISENTRESS 400 mg twice daily from STARTMRK are shown in Table 5.
Rezultati po 48. in 240. tednih preskušanja STARTMRK so za bolnike, ki so prejemali priporočeni odmerek 400 mg zdravila ISENTRESS dvakrat na dan, prikazani v preglednici 5.
Week 48 efficacy results
Rezultati učinkovitosti po 48 tednih
Week 48 outcomes (including outcomes by key baseline covariates) for SAILING are shown in Table 4.
Rezultati po 48 tednih (vključno z rezultati po ključnih osnovnih spremenljivkah) študije SAILING so prikazani v Preglednici 4.
Week 48 window is between day 309 and 364 (inclusive), week 96 window is between day 645 and 700 (inclusive).
Okno v 48. tednu je med 309. in 364. dnevom (vključno z njima), okno v 96. tednu je med 645. in 700. dnevom (vključno z njima).
Week 48 window is between Day 309 and 378 (inclusive).
Okno v 48. tednu je med 309 in 378 dnevom (vključno z njima).
Week 48 window was between Day 294 and 377 (inclusive).
Okno v 48. tednu je med 294. in 377. dnevom (vključno z njima).
Week 48 window was between Day 294 and 377 (inclusive); Week 96 window was between Day 630 and 713 (inclusive).
Okno v 48. tednu je med 294. in 377. dnevom (vključno z njima); okno v 96. tednu je med 630. in 713. dnevom (vključno z njima).
Week 48: -3% [-7.6%, 1.5%]
48. teden: -3% [-7,6%; 1,5%]
Week 48: 1.7% [-3.8%, 7.1%]
48. teden: 1,7% [-3,8%; 7,1%]
Week 48a
144. tednu
Week 48a
48. teden a
Week 4: 7 film-coated tablets of Nemdatine 20 mg
Teden 4: 7 filmsko obloženih tablet Nemdatine 20 mg
Week 4: Do not put on a patch this week.
4. teden: ta teden obliža ne uporabljajte.
Week 4: Take one tablet daily of Nemdatine 20 mg.
Teden 4: Vzemite 1 tableto zdravila Nemdatin 20 mg dnevno.
Week 5 + 6
5. + 6. teden
Week 5 All (N=11)
5. teden Vsi
Week 5 All (N=12)
5. teden Vsi
Week 5 All (N=23)
5. teden Vsi
Week 5 to 10
5. do 10. teden
Week 52
30,0
Week 52
40,0
Week 52
52.teden
Week 52
ocena po 52 tednihb
Week 52
po 52 tednih
Week 52 ACR20, n (%)
52. teden ACR20, n (%)
Week 52 mTSS
52. teden mTSS
Week 52 n (%)
52. teden n (%)
Week 52 scoreb
ocena po 52 tednihb